Public domain

Global Cancer Generics Market (2018 to 2026) - Reimbursement Policies & the Coverage Strategies by Country - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 18, 2020
Pharmaceutical, Health, Oncology, Health, Pharmaceuticals policy, Articles, Pharmaceutical industry, Generic drug, Public domain, Pharmaceutical industry in India, Dr. Reddy's Laboratories, Authorized generics

The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • It is a result of the extensive study conducted by analyzing the global companies for cancer generics.
  • Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
    Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
    Global Generics Market Growth 2018-2026: > 130%
    Global Cancer Generics Market Growth 2018-2026: 200%
    Comprehensive Insight On Cancer Generics Drugs: 43 Generics
    Cancer generics market gets highlighted by the minimal efforts drug makers have to put and the maximum advantages that the patients will receive.
  • The market of cancer generics is also escalating by the fact that the number of pharmaceuticals players interested in manufacturing generic drugs have been increasing.

A US-Based Generic Drugs Market Client Achieved Savings of Over $8.8 Million with Market Intelligence Engagement | RFP for Similar Engagement for Your Business

Retrieved on: 
Tuesday, March 17, 2020
General Health, Pharmaceutical, Health, Health, Articles, Pharmacy, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry, Prescription costs

Also, gather detailed insights into the approach undertaken by the experts at Infiniti Research to help the generic drugs market client achieve savings of over $8.8 million in a year.

Key Points: 
  • Also, gather detailed insights into the approach undertaken by the experts at Infiniti Research to help the generic drugs market client achieve savings of over $8.8 million in a year.
  • However, evolving governmental regulations and rising generic drug prices are expected to hamper the generic drugs market development.
  • As such, generic drugs manufacturers will need to foresee changing market dynamics and look for other markets to sustain growth.
  • Besides, the rising concerns about the safety and efficacy of extended-release generic drugs made it difficult for the generic drugs market client to promote their products.

Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2019 Business and Financial Update on March 18, 2020

Retrieved on: 
Thursday, March 12, 2020
Pharmaceutical industry, Articles, Life sciences, Generic drug, Pharmaceuticals policy, Public domain, Pharmaceutical industry in India, Industries

The webcast will be archived for 30 days at the aforementioned URL.

Key Points: 
  • The webcast will be archived for 30 days at the aforementioned URL.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Osmotica to Present at Barclays Global Healthcare Conference 2020

Retrieved on: 
Tuesday, March 3, 2020
Pharmaceuticals policy, Articles, Health, Life sciences, Pharmaceutical industry, Generic drug, Public domain, Pharmaceutical industry in India, Pharmaceutical industry in China

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Result of Placing under Placing Programme

Retrieved on: 
Wednesday, February 26, 2020
Initial public offering, Stock market, Prospectus, Financial economics, Finance, Insider trading, Public domain, Economy

Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Key Points: 
  • Upon the publication of this announcement, this inside information is now considered to be in the public domain.
  • A copy of the Prospectus is available for inspection at: www.morningstar.co.uk/uk/nsm as well as on the Company's website: https://www.aewukreit.com/ .
  • Terms used but not defined in this announcement shall have the meanings given to such terms in the Prospectus dated 1 March 2019.
  • Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Sketchfab Launches Public Domain Dedication for Cultural Heritage with the Smithsonian Institution and World-class Organizations

Retrieved on: 
Tuesday, February 25, 2020
Intellectual property law, WebGL, 3D graphics software, Sketchfab, Copyleft, Creative Commons, Public domain, 3D modeling, Mass media, Computer graphics

NEW YORK, Feb. 25, 2020 /PRNewswire-PRWeb/ -- Cultural organizations using Sketchfab can now dedicate their 3D scans and models to the Public Domain using the Creative Commons (CC) 0 Public Domain Dedication.

Key Points: 
  • NEW YORK, Feb. 25, 2020 /PRNewswire-PRWeb/ -- Cultural organizations using Sketchfab can now dedicate their 3D scans and models to the Public Domain using the Creative Commons (CC) 0 Public Domain Dedication.
  • Sketchfab made this announcement in collaboration with a long list of cultural organizations from all over the world.
  • Notably, the Smithsonian Institution joined this dedication with the upload of their first official 3D models to Sketchfab as part of their newly launched open access initiative.
  • Sketchfab's implementation of CC0 dedication for 3D cultural heritage content is in harmony with the ongoing trend of open access policies that are being adopted by many of the world's leading cultural organizations.

FDA approves first generic of ProAir HFA

Retrieved on: 
Tuesday, February 25, 2020
Health, Articles, Asthma, Dosage forms, Pharmaceuticals policy, Generic drug, Public domain, Inhaler, Food and Drug Administration, Metered-dose inhaler

As a result, too many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval.

Key Points: 
  • As a result, too many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval.
  • The FDA also publishes guidance documents describing the steps the FDA recommends companies take to submit complete applications for generic drug products.
  • In 2016, the FDA issued a revised draft product-specific guidance for proposed generic albuterol sulfate metered dose inhalers, including drug products referencing ProAir HFA.
  • In 2020, the FDA will continue to advance additional policies to promote generic competition for complex generic drug products .

Osmotica to Present at 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Tuesday, February 18, 2020
Pharmaceuticals policy, Articles, Health, Life sciences, Pharmaceutical industry, Generic drug, Public domain, Pharmaceutical industry in India, Pharmaceutical industry in China

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.

Key Points: 
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Vertical Pharmaceuticals, LLC represents the Companys diversified branded portfolio and Trigen Laboratories, LLC represents the non-promoted products including complex generic formulations.
  • Osmotica has operations in the United States, Argentina, and Hungary.

Top 5 Generic Opportunities in Pharmaceuticals to Watch in 2019: Perspective for the Future

Retrieved on: 
Tuesday, January 7, 2020
Health, Articles, Pharmaceuticals policy, Generic drug, Public domain, Pharmaceutical industry, Drug, Medication

In the last 3 decades the pharmaceutical market witnessed a shift from a blockbuster model to new business models owing to the influx of generic drugs.

Key Points: 
  • In the last 3 decades the pharmaceutical market witnessed a shift from a blockbuster model to new business models owing to the influx of generic drugs.
  • Generic basically mimic the original drug characteristics and show equivalence in therapeutic effect.
  • However, these class of drugs are cheaper and are easy to scale up when compared to original branded drugs.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Adamas Announces Settlement of Patent Litigation with Sandoz Inc.

Retrieved on: 
Thursday, January 2, 2020
RTT, Generic drug, Pharmaceutical industry, Pharmaceuticals policy, Public domain, Hypotension, Articles, Health, Life sciences

Upon entry of the joint stipulation and order, this Settlement Agreement will conclude all patent litigation brought to date by Adamas against generic pharmaceutical companies that filed an ANDA seeking approval to market generic versions of GOCOVRI prior to the expiration of the patents listed in the Orange Book.

Key Points: 
  • Upon entry of the joint stipulation and order, this Settlement Agreement will conclude all patent litigation brought to date by Adamas against generic pharmaceutical companies that filed an ANDA seeking approval to market generic versions of GOCOVRI prior to the expiration of the patents listed in the Orange Book.
  • The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.
  • At Adamas, our purpose is clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society.
  • Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.